Induction of differentiation of human myeloid leukemia cells by immunosuppressant macrolides (rapamycin and FK506) and calcium/calmodulin-dependent kinase inhibitors

Experimental Hematology

Volumn 29, Issue 5, 2001, Pages 582-588

  Yamamoto Yamaguchi, Yuri ^a   Okabe Kado, Junko ^a   Kasukabe, Takashi ^a   Honma, Yoshio ^a  

^a SAITAMA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; ASCOMYCIN; CD11B ANTIGEN; IMMUNOPHILIN; LYSOZYME; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; NITROBLUE TETRAZOLIUM; PROTEIN KINASE (CALCIUM,CALMODULIN); PROTEIN KINASE INHIBITOR; RAPAMYCIN; TACROLIMUS;

ANTIGEN EXPRESSION; ARTICLE; CELL DIFFERENTIATION; CELL LINE; CELL STRAIN HL 60; CONTROLLED STUDY; ENZYME ACTIVITY; GRANULOCYTE; HUMAN; HUMAN CELL; MYELOID LEUKEMIA; PRIORITY JOURNAL;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; BENZYLAMINES; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CELL DIFFERENTIATION; ENZYME INHIBITORS; HL-60 CELLS; HUMANS; IMMUNOPHILINS; IMMUNOSUPPRESSIVE AGENTS; K562 CELLS; LEUKEMIA, MYELOID; NEOPLASM PROTEINS; PROTEIN-SERINE-THREONINE KINASES; SIROLIMUS; SULFONAMIDES; TACROLIMUS; TACROLIMUS BINDING PROTEINS; TUMOR CELLS, CULTURED; U937 CELLS;

EID: 0035005721     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(01)00626-9     Document Type: Article

References (37)

1. Honma Y., Okabe-Kado J., Hozumi M., Uehara Y., Mizuno S. Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity. Cancer Res. 49:1989;331.
2. Honma Y., Okabe-Kado J., Kasukabe T., Hozumi M., Umezawa K. Inhibition of abl oncogene tyrosine kinase induces erythroid differentiation of human myelogenous leukemia K562 cells. Jpn J Cancer Res. 81:1990;1132.
3. Makishima M., Honma Y., Hozumi M., Sampi K., Hattori M., Motoyoshi K. Induction of differentiation of human leukemia cells by inhibitors of myosin light chain kinase. FEBS Lett. 287:1991;175.
4. Makishima M., Honma Y., Hozumi M.et al. Effects of inhibitors of protein tyrosine kinase activity and/or phosphatidylinositol turnover on differentiation of some human myelomonocytic leukemia cells. Leuk Res. 15:1991;701.
5. Okazaki T., Kato Y., Mochizuki T., Tashima M., Sawada H., Uchino H. Staurosporine, a novel protein kinase inhibitor, enhances HL-60-cell differentiation induced by various compounds. Exp Hematol. 16:1988;42.
6. Schreiber S.L. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science. 251:1991;283.
7. Price D.J., Grove J.R., Calvo V., Avruch J., Bierer B.E. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science. 257:1992;973.
8. Kuo C.J., Chung J., Fiorentino D.F., Flanagan W.M., Blenis J., Crabtree G.R. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature. 358:1992;70.
9. Kunz J., Hall M.N. Cyclosporin A, FK506, and rapamycin. more than just immunosuppression Trends Biochem Sci. 18:1993;334.
10. Brown E.J., Beal P.A., Keith C.T., Chen J., Shin T.B., Schreiber S.L. Control of p70 S6 kinase by kinase activity of FRAP in vivo. Nature. 377:1995;441.
11. Wiederrecht G., Etzkorn F. The immunophilins. Perspect Drug Discovery Design. 2:1994;57.
12. Dumont F.J., Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci. 58:1996;373.
13. Le Bihan S., Renoir J.M., Radanyi C.et al. The mammalian heat shock protein binding immunophilin (p59/HBI) is an ATP and GTP biding protein. Biochem Biophys Res Commun. 195:1993;600.
14. Baughman G., Wiederrechit G.J., Chang F., Martin M.M., Bourgeois S. Tissue distribution and abundance of human FKBP51, an FK506-binding protein that can mediate calcineurin inhibition. Biochem Biophys Res Commun. 232:1997;437.
15. Lebeau M.C., Massol N., Herrick J.et al. P59, an hsp 90-binding protein. Cloning and sequencing of its cDNA and preparation of a peptide-directed polyclonal antibody. J Biol Chem. 267:1992;4281.
16. Peattie D.A., Harding M.W., Fleming M.A.et al. Expression and characterization of human FKBP52, an immunophilin that associates with the 90 kDa heat shock protein and is a component of steroid receptor complexes. Proc Natl Acad Sci U S A. 89:1992;10974.
17. Le Bihan S., Marsaud V., Mercier-Bodard C.et al. Calcium/calmodulin kinase inhibitors and immunosuppressant macrolides rapamycin and FK506 inhibit progestin- and glucocorticosteroid receptor-mediated transcription in human breast cancer T47D cells. Mol Endocrinol. 12:1998;986.
18. Renoir JM, Marsaud V, Mercier-Bodard C, Le Bihan S, Radanyl C, Baulieu EE (1996) Modulation of steroid-induced transcription by cyclophilin and FKBPs. In: Workshop on Cyclophilin Structure and Function, October 10-12 1996, Life, France, Centre National de la Recherche Scientifique and Universite des Sciences et Technologies de Lille, France, 117.
19. 3-induced upregulation of calcineurin during leukemic HL-60 cell differentiation. Blood. 87:1996;2947.
20. Kihira H., Hiasa A., Yamamoto M.et al. Possible involvement of calcineurin in retinoic acid-induced inhibition of leukemic HL-60 cell proliferation. Int J Oncol. 12:1998;629.
21. Albers M.W., Williams R.T., Brown E.J., Tanaka A., Hall F.L., Schreiber S.L. FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-cdk association in early G1 of an osteosarcoma cell line. J Biol Chem. 268:1993;22825.
22. Metcalfe S.M., Canman C.E., Milner J., Morris R.E., Goldman S., Kastan M.B. Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells. Oncogene. 15:1997;1635.
23. S6-kinase pathway induces B16 melanoma cell differentiation. J Biol Chem. 271:1996;31824.
24. Jayaraman T., Marks A.R. Rapamycin-FKBP12 blocks proliferation, induces differentiation, and inhibits cdc2 kinase activity in a myogenic cell line. J Biol Chem. 268:1993;25385.
25. Ogawa T., Tokuda M., Tomizawa K.et al. Osteoblastic differentiation is enhanced by rapamycin in rat osteoblast-like osteosarcoma (ROS 17/2.8) cells. Biochem Biophys Res Commun. 249:1998;226.
26. Yeh W.C., Bierer B.E., McKnight S.L. Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells. Proc Natl Acad Sci U S A. 92:1995;11086.
27. Yamamoto-Yamaguchi Y., Makishima M., Kanatani Y., Kasukabe T., Honma Y. Reversible differentiation of human monoblastic leukemia U937 cells by ML-9, an inhibitor of myosin light chain kinase. Exp Hematol. 24:1996;682.
28. Tokimitsu H., Chijiwa T., Hagiwara M., Mizutani A., Terasawa K., Hidaka H. KN62, 1-[N,O-bis (5-isoquinolinesulfonyl)-N-methyl-1 tyrosyl] 4-phenylpiperazine, a specific inhibitor of Ca++/ calmodulin-dependent protein kinase II. J Biol Chem. 265:1990;4315.
29. +1/calmodulin dependent protein kinase II inhibitor KN93 reduces dopamine content in PC12h cells. Biochem Biophys Res Commun. 181:1991;968.
30. s6k integrates phosphatidylinositol 3-kinase and rapamycin-regulated signals for E2F regulation in T lymphocytes. Mol Cell Biol. 19:1999;4729.
31. Peterson R.T., Desai B.N., Hardwick J.S., Schreiber S.L. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycin-associated protein. Proc Natl Acad Sci U S A. 96:1999;4438.
32. s6K pathway in human pancreatic cancer cells. Cancer Res. 59:1999;3581.
33. Hoof T., Demmer A., Christians U., Tummler B. Reversal of multidrug resistance in Chinese hamster ovary cells by the immunosuppressive agent rapamycin. Eur J Pharmacol. 246:1993;53.
34. Arceci R.J., Stieglitz K., Bierer B.E. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood. 80:1992;1528.
35. Houchens D.P., Ovejera A.A., Riblet S.M., Slagel D.E. Human brain tumor xenografts in nude mice as s chemotherapy model. Eur J Cancer Clin Oncol. 19:1983;799.
36. Eng C.P., Sehgal S.N., Vezina C. Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiotics. 37:1984;1231.
37. Makishima M., Honma Y., Hozumi M.et al. Differentiation of human myeloblastic leukemia ML-1 cells into macrophages by staurosporine, an inhibitor of protein kinase activities. Exp Hematol. 21:1993;839.